Yuquan Mao1, Guojie Hu2, Qingyan Meng3, Xiaoyuan Li4, Xiaowei Sun5, Jie Zhou6, Tingting Zhang7, Hui Liu8, Chunhong Wang9, Xin Du10. 1. Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: valleyspring@126.com. 2. Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: huguojie2003@163.com. 3. College of Basic TCM, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: mqytcm@qq.com. 4. Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: veronicalm@163.com. 5. Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: sunxiaowei-00@163.com. 6. Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: ms.zhoujie@163.com. 7. Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: zhangtingting514@163.com. 8. Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: liuhuitcm@163.com. 9. Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: drchhw@126.com. 10. Reproductive Health Center, Women and Children's Hospital, Qingdao University, Qingdao, China. Electronic address: 102796@qdfe.com.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Shenling Baizhu San (SBS) as a classic Chinese medicine prescription, has been extensively used in gastrointestinal diseases, such as ulcerative colitis and chronic diarrhea. In recent years, SBS has shown a beneficial effect on chronic obstructive pulmonary disease (COPD) patients. However, clinical trials had shown conflicting results of SBS on improving pulmonary function and other related indicators of patients with stable COPD. The efficacy of SBS on stable COPD patients has not been fully assessed. AIM OF THE STUDY: To determine whether the SBS used in the treatment of gastrointestinal disease was effective to treat COPD, we assessed the clinical evidence and efficacy of SBS supplemental treatment on stable COPD patients by a systematic review and meta-analysis of clinical trials. MATERIALS AND METHODS: Nine electronic databases were searched to include clinical trials (published until August 31, 2020) with SBS as a supplementation treatment on stable COPD. Mean difference (MD) was used to evaluate continuous variables, odds ratio (OR) was calculated to evaluate dichotomous. The Egger's test was applied for publication bias. RESULTS: A total of 770 COPD participants from 11 trials that met the inclusion criteria were included. The meta-analysis showed that modified SBS could improve the exercise endurance, life quality scores of stable COPD patients, and also showed the potential benefits to pulmonary function of COPD patients than original SBS. CONCLUSION: The methodological quality of included trials may limit the conclusions that indicate that modified SBS may have a promising treatment for improving FEV1/FVC and MVV, increasing exercise endurance and life quality scores on stable COPD patients.
ETHNOPHARMACOLOGICAL RELEVANCE: Shenling Baizhu San (SBS) as a classic Chinese medicine prescription, has been extensively used in gastrointestinal diseases, such as ulcerative colitis and chronic diarrhea. In recent years, SBS has shown a beneficial effect on chronic obstructive pulmonary disease (COPD) patients. However, clinical trials had shown conflicting results of SBS on improving pulmonary function and other related indicators of patients with stable COPD. The efficacy of SBS on stable COPDpatients has not been fully assessed. AIM OF THE STUDY: To determine whether the SBS used in the treatment of gastrointestinal disease was effective to treat COPD, we assessed the clinical evidence and efficacy of SBS supplemental treatment on stable COPDpatients by a systematic review and meta-analysis of clinical trials. MATERIALS AND METHODS: Nine electronic databases were searched to include clinical trials (published until August 31, 2020) with SBS as a supplementation treatment on stable COPD. Mean difference (MD) was used to evaluate continuous variables, odds ratio (OR) was calculated to evaluate dichotomous. The Egger's test was applied for publication bias. RESULTS: A total of 770 COPDparticipants from 11 trials that met the inclusion criteria were included. The meta-analysis showed that modified SBS could improve the exercise endurance, life quality scores of stable COPDpatients, and also showed the potential benefits to pulmonary function of COPDpatients than original SBS. CONCLUSION: The methodological quality of included trials may limit the conclusions that indicate that modified SBS may have a promising treatment for improving FEV1/FVC and MVV, increasing exercise endurance and life quality scores on stable COPDpatients.